Traditionally regarded to coordinate movement, the cerebellum also exerts non-motor functions including the regulation of cognitive and behavioral processing, suggesting a potential role in neurodegenerative conditions affecting cognition, such as Alzheimer's disease (AD). This study aims to investigate neuropathology and ADrelated molecular changes within the neocerebellum using post-mortem human brain tissue microarrays (TMAs).
attention, often serving as control tissue or a reference region in AD studies (Smith et al., 1997; Dukart et al., 2010) .
Traditionally, the cerebellum was widely regarded as a structure controlling motor regulation such as movement, gait, posture, motor coordination and learning (Albus, 1971; Thach, 1996; Wegiel et al., 1999) . However, recent clinical and neuroimaging studies have demonstrated that the cerebellum exerts non-motor functions such as cognitive, behavioral and affective processing (Schmahmann and Sherman, 1998; Schmahmann et al., 2001; Baumann et al., 2015) . In addition, the description of cerebellar cognitive affective syndrome (CCAS), a condition characterized by the presence of cerebellar lesions, includes hallmark deficits in executive function, linguistic processing, visuospatial cognition and emotional modulation. This clinical evidence supports the hypothesis that changes in the cerebellum lead to compromised cognitive and affective functions, rather than just motor symptoms (Schmahmann and Sherman, 1998; Schmahmann, 2004) .
Pathological changes within the cerebellum have been reported in AD by early descriptive and semi-quantitative studies in human tissue. Cerebellar amyloid-β deposits have been frequently reported within the molecular, granular and Purkinje cell layers of the cerebellar cortex (Braak et al., 1989; Joachim et al., 1989; Dickson et al., 1990; Li et al., 1994; Fukutani et al., 1997; Wegiel et al., 1999; Wang et al., 2002) . In contrast, neurofibrillary tau tangles are largely absent (Joachim et al., 1989; Li et al., 1994; Wegiel et al., 1999; Yamamoto and Hirano, 1985) . Semi-quantitative studies have reported a loss of Purkinje cells within the AD cerebellum compared to control brains (Sjöbeck and Englund, 2001; Wegiel et al., 1999) . However, a recent stereological cell counting study reported no overall loss of Purkinje cells, suggesting that neuronal cell bodies are widely intact in the AD cerebellum (Andersen et al., 2012) . Since this study, the literature concerning AD cerebellar neuropathology has been limited to predominantly historical observations.
Interestingly, the importance of the cerebellum in neurodegenerative conditions such as frontotemporal dementia and AD has recently been gaining traction in patient neuroimaging and proteomics studies (Bas et al., 2009; Canu et al., 2010; Guo et al., 2016; Xu et al., 2018) . Recent functional neuroimaging studies in humans and previous tracing studies in animal brains have documented the extensive, topographically-organized connections between the cerebral cortex and cerebellum (Haines et al., 1997; Haines and Dietrichs, 1984; Siwek and Pandya, 1991; Habas et al., 2009; Buckner et al., 2011) . Notably Guo et al. (2016) reported that cerebellar regions with greater atrophy (cerebellar crus I and II) are those connected via cerebral 'default modes' to regions of the cerebral cortex (bilateral angular gyrus, precuneus and posterior cingulate cortex) which are more vulnerable to AD degeneration (Guo et al., 2016) . Together, these findings of alterations in the cerebellum in recent neuroimaging studies suggest that the cerebellum is not a "silent bystander" or a mere "reference point" for neuroanatomical studies of AD (Guo et al., 2016; Schmahmann, 2016) . A recent proteomics study mapped the relative levels of over 5000 distinct proteins within n = 9 AD and n = 9 control human cases from the Neurological Foundation of New Zealand Human Brain Bank (Xu et al., 2018) . Unexpectedly, 120 proteins demonstrated cerebellarspecific changes which included proteins involved in dysregulation of the mitochondrial electron transport chain. Therefore, in light of recent clinical neuroimaging studies supporting network-selective vulnerability of the cerebellum to AD, the recognition of the cerebellum in non-motor circuits relating to cognition, combined with the identification of cerebellar-specific protein changes in AD using proteomics, suggest that there would be great merit in conducting a robust examination into the AD-related molecular changes within the human cerebellum at the cellular level.
The aim of this study is to utilize a tissue microarray (TMA) screening approach to examine molecular changes in the human AD neocerebellum, with a focus on neuropathological hallmarks, Purkinje cells, and non-neuronal cells involved in neuroinflammation and cerebrovascular dysfunction including microglia, endothelial cells, perivascular cells, and basement membrane-associated molecules. We hypothesize that the human cerebellum will present with changes in non-neuronal cells including microglia and vascular cells, based on the accumulation of literature suggesting that neuroinflammation and cerebrovascular dysfunction may precede the onset of neurodegenerative changes in AD and animal models (Bell and Zlokovic, 2009; Lepelletier et al., 2017; Heppner et al., 2015) . Because historical neuropathological studies have found a lesser degree of AD pathology in the cerebellum compared to cortical regions, the identification in the cerebellum of more subtle AD-related molecular changes which would be difficult to detect in more severely degenerated regions, provides the possibility of detecting early drivers of AD pathogenesis.
Materials and methods

Human tissue collection and processing
All post-mortem human brain tissue used in this study was obtained from the Neurological Foundation of New Zealand Human Brain Bank in the Centre for Brain Research, University of Auckland. All protocols in this study were approved by the University of Auckland Human Participants Ethics Committee (2008/279 and 011654) , and all families provided informed consent. All cases were examined by an independent neuropathologist and were classified based on neurological abnormalities, or lack thereof in neurologically normal control cases. To confirm a diagnosis of Alzheimer's disease (AD), the cases were pathologically classified according to the age-related plaque score (ARP) as outlined by the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) for cases received prior to (2008) (Mirra et al., 1991) . Cases received after (2008) were also classified according to Braak and Braak staging (I-VI) (Braak and Braak, 1991; Braak and Braak, 1995) .
Fixation and dissection protocols for human brain tissue preparation have been described previously (Waldvogel et al., 2007; Waldvogel et al., 2008) . Briefly, the brains were perfused and in each case the cerebellum was cut into four equal sized blocks from lateral to medial (CB0, CB1, CB2, and CB3) regions of the cerebellum, as shown in Fig. 1 . For this study, the CB1 block of the neocerebellum from the right cerebellar hemisphere was used ( Fig. 1) . A small portion of the block (~3 mm thick section) was embedded in paraffin for paraffin immunohistochemistry and tissue microarray (TMA) production, while the bulk of the block was post-fixed by immersion, cryoprotected, frozen using powdered dry ice, and stored at −80°C until preparation for free-floating immunohistochemistry. Fig. 1 . Preparation of human cerebellum for tissue microarray and immunohistochemistry. In this study, the human cerebellum was dissected into four equal-sized blocks, from lateral to medial (blocks 0-3). Block 1 from the mid-region of neocerebellum was selected for this study. A small portion of the block (~3 mm thick section) was embedded in paraffin for paraffin immunohistochemistry and tissuemicroarray (TMA) production. The remainder of the block was post-fixed and prepared for free-floating immunohistochemistry.
A total of 24 control cases with no history of neurological abnormalities (Table 1) and 24 AD cases with confirmed AD pathology and a clinical history of dementia (Table 2) were used for cerebellar paraffin TMA studies. The control and AD cases were matched as closely as possible for age at death and post-mortem delay. The control cases included 7 females and 17 males, aged 49-89 (mean = 72.3 ± 9.5 years), with a post-mortem delay of 5-48 h (mean = 14.1 ± 9.3 h). The AD cases included 14 females and 10 males, aged 51-87 (mean = 75.0 ± 8.8 years), with a post-mortem delay of 4-36 h (mean = 14.2 ± 7.8 h). To validate the TMA results, whole neocerebellar section analysis was conducted for 6 control cases (Table 3) and 6 AD cases (Table 4 ) using free-floating immunohistochemistry.
TMA design and production
Brain tissue donor blocks containing neocerebellum (block CB1) from n = 24 control and n = 24 AD cases (Tables 1 and 2) were fixed, dehydrated and processed for wax embedding as described previously (Waldvogel et al., 2007) . Five 7 μm thick sections were cut from each donor block using a paraffin microtome (RM2235, Leica) and mounted onto positively charged slides (Grale HDS) for antigenicity and neuroanatomical localisation studies utilising standard paraffin immunohistochemistry and cresyl violet staining procedures. One section from each donor block was immunolabelled for glial fibrillary acidic protein (GFAP, mouse anti-human, Sigma [G3893], 1:5000), which was selected based on the ubiquitous presence of the protein in both control and AD tissue. All donor blocks immunolabelled successfully with GFAP, which indicated an absence of fixation irregularities which could affect paraffin immunohistochemistry. An additional 7 μm section from each case was labelled with cresyl violet for neuroanatomical identification of a candidate cerebellar folium to core for TMA production.
The 48 selected donor blocks were incubated at 37°C overnight prior to core extraction. The Advanced Tissue Arrayer (VTA-100, Veridiam) was used to extract 2 mm tissue cores from the control and AD donor blocks (Narayan et al., 2015a) . The coring site was selected based on assessment of the cresyl violet stained sections, which included the presence of a complete folium containing the molecular, Purkinje and granular cell layers. A single cerebellar folium ≤2 mm in total size was identified in each donor block, cored, and inserted into a blank recipient TMA paraffin block to form an array of cores. Once all donor cores had been extracted and inserted into the recipient TMA block, the block was incubated overnight at 37°C, followed by 8 min incubation at 60°C. This heating process allowed the paraffin between each core and the recipient paraffin block to anneal and amalgamate, allowing the cores to adhere to the recipient block. Once cooled to room temperature, the recipient block was cut into 7 μm thick sections serially using the paraffin microtome. Due to the varying core cylinder lengths within the recipient block (between 4 and 6 mm) which depended on the tissue thickness from the original donor blocks, only a subset of sections contained all 24 control and 24 AD cores. Approximately 100 sections were obtained from this TMA containing 20+ cores from control and 20+ cores from AD donor blocks. Each cut section was mounted serially onto positively charged slides within a hot water bath at 38-39°C. Blank 2 mm cores that were inserted into the TMA within certain rows were used to ensure consistency in TMA section orientation during mounting. Once mounted and dried overnight at room temperature, the TMA sections were stored at room temperature until required for paraffin immunohistochemistry. The TMA used in this study is known as TMA 15.
Tissue microarray immunohistochemistry
Standard immunohistochemistry protocols were applied, as described previously (Waldvogel et al., 2007; Narayan et al., 2015a; Coppieters et al., 2014) . A summary of primary, secondary, and tertiary antibodies, in addition to antigen retrieval protocols can be found in Table 5 . The TMA sections were placed on a heating block at 60°C for 1 h to anneal the mounted tissue onto the glass slide and aid paraffin dewaxing. The slides were subsequently dewaxed, via xylene immersion twice (1 h and 10 min respectively), and rehydrated in 100% ethanol twice for 5 min, followed by 2 min each in 95%, 80% and 75% ethanol and 3 washes in milliQ H 2 O for 5 min. Heat-induced antigen retrieval was achieved through immersion in antigen retrieval buffer for 2 h at 121°C in a pressure cooker (model 2100-retriever, Pick Cell Laboratories). For tau and amyloid-β immunohistochemistry, once the slides had cooled post-antigen retrieval, an additional incubation in 99% formic acid was carried out for 5 min followed by 3 washes in milliQ H 2 O. Endogenous peroxidases were quenched with a 20 min incubation in endogenous peroxidase blocking solution (50% methanol, 1% H 2 O 2 , diluted in milliQ H 2 O) at room temperature. The slides were subsequently washed 3 times in PBS (phosphate-buffered saline) before exposure to a blocking buffer (either 10% normal goat or donkey serum in PBS) for 1 h at room temperature. Post serum block, the slides were incubated with the primary antibodies overnight at 4°C. The following day, the slides were washed first in PBS-T (phosphate-buffered saline with 0.2% Triton X-100) for 5 min, and twice in PBS for 5 min each, before the secondary antibody incubation was performed for 3 h at room temperature. The slides were washed again before the ExtrAvidin peroxidase (Sigma, 1:1000) incubation was carried out for 1 h at room temperature. Another washing step was conducted before incubating the slides in the peroxidase substrate (0.5% 3,3′-diaminobenzidine (DAB)), 0.01% H 2 O 2 intensified with 0.04% nickel ammonium sulfate until the colour reaction was visible. The peroxidase substrate was washed off using PBS and milliQ H 2 O (3 times, 5 min each for both PBS and milliQ H 2 O). The slides were dehydrated (2 min each in 75%, 80% and 95% ethanol, 5 min in 100% ethanol twice, and three times in xylene for 10 min each) before applying a coverslip using DPX mounting medium (Merck). The blocking, antibody and ExtrAvidin incubations were performed in a humidity chamber to prevent sections from drying out. Antibodies and ExtrAvidin were diluted in goat or donkey immunobuffer (1% normal goat or donkey serum in PBS). No- a AD pathological grades were designated with an age-related plaque (ARP) score with "A" reflecting low number of plaques and "C" reflecting a high number of plaques; or BRAAK staging with "III" reflecting the pathological presence of neurofibrillary tangles in the entorhinal, transentorhinal, limbic allocortex and adjoining neocortex, and "VI" reflecting the presence of tangles in all aforementioned areas, in addition to the wider neocortex including the secondary and primary fields. primary controls, where the primary antibody is omitted from the immunobuffer was performed for each antibody to assess the degree of nonspecific labelling due to the secondary antibody.
Free-floating immunohistochemistry
To validate significant findings from the cerebellar TMA, freefloating immunohistochemistry was conducted on 3 neocerebellar sections (a lateral, middle and medial section) obtained from block CB1 from n = 6 control and n = 6 AD cases (Tables 3 and 4) using standard single peroxidase labelling techniques as detailed previously (Waldvogel et al., 2007; Coppieters et al., 2014; Narayan et al., 2015b) . Briefly, 50 μm cut sagittal neocerebellar sections were permeabilized in PBS-T overnight at 4°C in six-well tissue culture plates. Upon PBST removal, the sections were immersed in antigen retrieval buffer and placed into a 650 watts microwave oven for 40 s (until boiling) and allowed to cool at room temperature. Endogenous peroxidases were quenched with a 30 min incubation in 50% methanol, 1% H 2 O 2 , diluted in milliQ H 2 O at room temperature. Sections were incubated in primary antibodies for 3 days at 4°C. Sections were subsequently incubated with the corresponding biotinylated secondary antibody overnight at room temperature, followed by ExtrAvidin peroxidase for 4 h at room temperature. Finally, the sections were incubated in 0.5% 3,3′-diaminobenzidine, 0.01% H 2 O 2 intensified with 0.04% nickel ammonium sulfate until the colour reaction was visible (10-20 min). The sections were carefully mounted in gelatin onto slides, allowed to dry for 1-2 days before dehydration through the following series: 5 min in 75%, 85% and 95% ethanol, 10 min in two lots of 100% ethanol, and three 20 min immersions in xylene before being coverslipped with DPX mounting medium (Merck). A no-primary antibody condition was used as a negative control for each antibody. Three 10 min washes were conducted with PBS-T between every step post-antigen retrieval. Antibodies and ExtrAvidin peroxidase incubations were diluted in goat or donkey immunobuffer (1% normal goat/donkey serum in PBS-T containing 0.04% thimerosal). The antibodies in this present study have been widely used, and their specificities have been previously validated by western blotting, immunocytochemistry and immunohistochemistry in human tissue by independent researchers (Table 5) .
Image acquisition
Images were acquired for each immunolabelled TMA slide using a VSlide automated slide scanning microscope (Metasystems) running Metafer4 software (version 3.12.133) utilising a TMA imaging protocol outlined by Narayan et al. (2015a) . Briefly, an initial automated lowpower pre-scan of the TMA was generated using a 2.5× objective lens. The pre-scan image was opened using the 'Microarray Tool' function within Metafer4 software, and threshold based segmentation was performed to localise the immunolabelled cores. A 6 × 10 grid of interconnected 'dots' were placed over the thresholded cores, and each 'dot' was manually placed in the centre of each core of interest. Once the centre of each core was finalised, a subsequent automated re-scan was carried out for each core at 10× magnification across the entire TMA in a high-throughput, standardised fashion. Four images were acquired around the centre for each core in order to capture the entire 2 mm core with sufficient detail. Images acquired were automatically saved with individual filenames corresponding to the core coordinates. The re-scan images were inspected for cores containing folded, missing, or torn tissue which were excluded from subsequent analysis.
Whole neocerebellar sections were imaged using the 'Rescan Region of Interest (ROI)' setting of the VSlide scanner running Metafer4 software. In brief, a slide size of 76 × 60 mm was selected, and a pre-scan of the whole slide was generated using a 2.5× objective lens. The prescan image was automatically stitched together and saved into a 'MetaClient' directory. The image was reopened with Metaviewer, where contours were drawn over the stitched pre-scan to delineate the ROI for a higher resolution re-scan. The ROI included all cerebellar branches to capture every folium within the sagittal section. Once the contour was complete, the ROI was re-scanned automatically using a 10× objective lens, resulting in 1000-2000 images captured within the defined ROIs per slide. The re-scan images were manually scrutinised, and images with folded, torn, or absent cerebellar folia were excluded from analysis.
Image analysis using high-content screening
The images acquired were analysed using Metamorph software (Metamorph Offline v.7.8.0, Molecular Devices). Image analysis for the TMA cores were conducted using the 'Count Nuclei algorithm' (Narayan and Dragunow, 2010) . For each immunolabel, Count Nuclei measurements logged within an excel spreadsheet included the following: total nuclei (if cells were quantified), total area (of the immunolabel) and integrated intensity. In addition, the whole area of each core was determined using the 'Threshold Image' command. Thresholding applied segmentation to an image by taking objects of interest (in this case, the whole core) that were above a pre-defined grayscale value. Once the core was isolated, the thresholded area was logged using the 'Show Region Statistics' function. Therefore, TMA data for each immunolabel presented here includes the integrated intensity (total intensity of immunolabel) and load (area of immunolabel as a percentage of total area of the core) expressed as a mean of 4 images per core. For CD31 vessel quantification, a custom analysis workflow was created to quantify longitudinal and transverse vessels. The workflow identified vascular staining that met user-defined size and intensity criteria; the Adaptive Threshold tool was used to measure the area and integrated intensity of all vessel staining; the Angiogenesis Tube Formation tool quantified a All AD cases selected had advanced AD pathology, represented with an age-related plaque (ARP) score of "C" reflecting a high number of plaques; or BRAAK staging of V-VI reflecting widespread neurofibrillary tangles (severe AD pathology).
Table 5
Antibodies and conditions used to study the Alzheimer's cerebellum. longitudinal vessels and associated branch points; the Count Nuclei tool counted transverse vessels in images from which the longitudinal vessels were subtracted. All measurements were normalised to the total imaged area for that core. Analysis for whole cerebellar sections immunolabelled with freefloating immunohistochemistry were conducted using the same Metamorph journals as described for TMA analysis. However, integrated intensities which we found to alter in AD sections were also replotted as integrated intensity per immunopositive cell to account for variability in cell number between control and AD cases (Coppieters et al., 2014) . In addition, for microglial morphology measurements within sections (IBA1 and HLA-DR), the 'Neurite Outgrowth' module was used to generate segmentation masks specific for IBA1 and HLA-DR immunolabels (Narayan et al., 2015a) . The Neurite Outgrowth measurements logged included: mean outgrowth per cell, mean processes per cell and mean branches per cell. The data for whole sections were presented as a mean of all images quantified per case.
Statistical analysis
Data obtained from the Metamorph software were statistically analysed using GraphPad Prism (version 7.03). The mean AD and control data from TMA and whole section validation were screened for normality and homoscedasticity. Normality was graphically assessed using a dot plot of the data, where the data was considered to be normal if 95% of data points fell within two standard deviations of the mean. The D'Agostino-Pearson omnibus test also assessed normality using GraphPad Prism. Data was considered normally distributed if p < 0.05. The Brown-Forsythe test assessed homoscedasticity, where p < 0.05 was considered to be groups with unequal variances. Based on dot plot screening, normality and homoscedasticity tests, the majority of the control and AD TMA data for each immunolabel were from a Gaussian population. Therefore, the comparisons between AD and control groups for TMA data were conducted using a 2-tailed Student's unpaired t-test with Welch's correction for unequal variances. Subgroup comparisons within the AD and control groups (such as gender comparisons) utilized Kruskal-Wallis test combined with Dunn's multiple comparisons post-test due to departures from normality. The control and AD data analysed from free-floating whole sections were compared using a 2-tailed Mann-Whitney test due to departures from normality and unequal variances. A p-value ≤0.05 was considered statistically significant (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). Results were presented as mean ± standard deviation.
Results
Extent of cerebellar neuropathology in AD
The results of tissue microarray (TMA) analysis demonstrated a significant increase in amyloid-β (Aβ) expression and coverage within the AD cerebellum ( Fig. 2a-d) , with a 433% increase in Aβ integrated intensity (p = 0.01) and 1482% increase in load (p = 0.007). In comparison, TMA analysis of tau expression and coverage ( Fig. 2e-f ) indicated no significant differences between AD and control cohorts. However, a small subset of AD cases with tau-positive circular-shaped staining (Fig. 2h ) are represented as outliers in Fig. 2e-f . TMA analysis of ubiquitin ( Fig. 2i-l) in AD compared with control cores demonstrated no significant differences in expression and coverage. To assess Purkinje cells in the cerebellum (Fig. 2m-p) , TMA analysis of cell number and expression of calbindin-positive Purkinje cell bodies revealed no differences between the AD and control cohorts.
3.2. Increase in IBA1 expression and altered IBA1 microglial morphology in AD neocerebellum tissue TMA analysis of IBA1 microglia revealed a significant increase in expression and coverage within AD cerebellar cores ( Fig. 3a-b) , with a 91% increase in integrated intensity (p = 0.002) and 69% increase in load (p = 0.01). To understand the contribution of cellular morphology and cell number to the increased cerebellar IBA1 expression in AD TMAs, 1000-2000 images were analysed from 3 whole neocerebellar sections from control (n = 6) and AD (n = 6) cases ( Fig. 3c-f ). No significant differences in IBA1 microglial cell number (Fig. 3c ) was found between the control and AD cases, which suggests that the elevation in IBA1 expression and coverage is not attributable to differences in cell number. However, IBA1 expression in these whole sections normalised to cell number to give IBA1 integrated intensity per cell was significantly increased by 27% (p = 0.03) in AD, thus reinforcing greater IBA1 expression within individual IBA1-positive microglia (Fig. 3d) . Quantitative (Fig. 3e-f ) examination of IBA1-positive microglial morphology in whole neocerebellar sections revealed a significant reduction in process length per cell (22% reduction, p = 0.03) and branches per cell (41% reduction, p = 0.03) within the AD cases. AD IBA1-positive microglia appear to be less ramified ( Fig. 3g-h) , possess fewer branches, and widely appear hypertrophic compared to control microglia.
3.3. Presence of deramified dystrophic HLA-DR-positive microglia in AD neocerebellum tissue TMA analysis revealed no significant changes in HLA-DR expression or coverage ( Fig. 4a-b ). Subsequent HLA-DR cell counts were conducted for 1000-2000 images obtained from 3 neocerebellar sections for control (n = 6) and AD (n = 6) cases (Fig. 4c ), revealing no differences in HLA-DR-positive microglial cell number. Quantitative (Fig. 4d-e ) examination of HLA-DR-positive microglial morphology in whole neocerebellar sections revealed a significant reduction in process length per cell (33% reduction, p = 0.009) and branches per cell (49% reduction, p = 0.004) within the AD cases. HLA-DR-positive microglia within the AD neocerebellum showed considerable abnormalities compared to control cases ( Fig. 4f-g) , with shortened, fragmented, deramified and beaded processes, indicating that they are dystrophic.
Absence of GFAP astrocytic changes in AD neocerebellum tissue
TMA analysis revealed no significant changes in GFAP expression or coverage in AD ( Fig. 5a-b ). GFAP immunoreactivity was extensive within both control and AD neocerebellar folia ( Fig. 5c-d) , with abundant fibrous staining, particularly within the granule cell layer, which made the identification of cell bodies difficult for any further quantification. Closer examination of GFAP-positive astrocytes (insets, Fig. 5c d) showed similar morphologies in the AD and control folia, suggestive of a resting astrocytic phenotype and an absence of astrogliosis in the AD cerebellum.
Increase in vascular fibronectin in AD neocerebellum tissue with no change in collagen IV
TMA analysis of vascular fibronectin expression ( Fig. 6a ) revealed a significant 27% increase in integrated intensity (p = 0.04) in AD cerebellar cores, with no change in overall fibronectin load (Fig. 6b ). Qualitative examination of fibronectin immunoreactivity within the cerebellar molecular layer of whole cerebellar sections reinforces the TMA data ( Fig. 6c-f ) with more intense immunoreactivity throughout AD capillaries compared to control cases. TMA analysis of collagen IV (Additional file 1: Supplementary Fig. 1a-d) in AD compared with control cores demonstrated no significant differences in expression and coverage.
3.6. Greater number of CD31 vessels in AD neocerebellum tissue TMA analysis of vascular CD31 demonstrated a significant increase in CD31 expression and coverage within the AD cerebellum ( Fig. 7a-b) , with a 114% increase in CD31 integrated intensity (p = 0.006) and 115% increase in load (p = 0.001). To investigate the relative contributions of vessel number and CD31 expression per vessel to the increase in CD31 integrated intensity, the number of CD31 vessels were quantified and the expression of CD31 was reanalyzed and normalised to vessel number ( Fig. 7c-d) . The number of CD31-positive vessels was found to be significantly increased by 98% (p = 0.02) in AD cases relative to controls (Fig. 7c ). Normalizing the expression of CD31 to vessel number revealed no significant differences between control and AD cores (Fig. 7d) , which reinforces that the greater expression and coverage of CD31 in the AD neocerebellum is attributable to a greater number of vessels in AD. Qualitative examination of CD31 immunoreactivity within the cerebellar molecular layer of whole sections reinforces the TMA data ( Fig. 7e-f ) with considerably greater numbers of CD31-positive vessels present in the AD neocerebellum relative to controls.
No change in mural cells in AD neocerebellum tissue
TMA analysis of mural cell markers platelet-derived growth factor receptor beta (PDGFRβ) and alpha smooth muscle actin (αSMA) in AD compared with control cases demonstrated no significant differences in overall expression or coverage (Additional file 1: Supplementary   Fig. 2 . Quantification of Aβ, tau, ubiquitin and calbindin immunoreactivity in control and AD cerebellar tissue microarray cases. Integrated intensity and load measurements were used to quantify the AD neuropathological hallmarks (a-d) Aβ, (e-h) tau, and (i-l) ubiquitin levels in TMA 15. A significant increase in Aβ levels were found in AD (n = 22) compared to control (n = 24) cases, evidenced by (a) a 433% increase in Aβ integrated intensity (p = 0.01) and (b) a 1482% increase in Aβ load (p = 0.007). (c-d) Photomicrographs of TMA paraffin cores from (c) representative control case H239 and (d) AD case AZ46. White arrowheads denote the presence of Aβ plaques. No significant differences were observed in tau immunoreactivity between control (n = 22) and AD (n = 20) in terms of tau (e) integrated intensity (p = 0.076) and (f) load (p = 0.074). No Tau immunoreactivity was identified within control TMA paraffin cores, as illustrated in (g) representative control case H123. A small subset of AD cases contained tau-positive circular structures (h) as demonstrated with a white arrowhead in representative AD case AZ101. A high power inset of (h') tau-positive immunoreactivity within the granule cell layer of AD case AZ101 illustrates the unusual doughnut-shape appearance of the structure. No tau-positive neurofibrillary tangles were identified within the AD cores examined. No differences were observed in ubiquitin immunoreactivity between control (n = 24) and AD (n = 24) cases in terms of ubiquitin (i) integrated intensity (p = 0.99) and (j) load (p = 0.73). Ubiquitin immunoreactivity was identified in photomicrographs of control and AD TMA paraffin cores, denoted with white arrows in (k) representative control case H239 and (l) AD case AZ46. To assess Purkinje cells in TMA 15, calbindin immunoreactivity (m-p) was quantified. No differences were observed in calbindin (m) integrated intensity (p = 0.55) or (n) calbindinpositive Purkinje cell counts (p = 0.27) between control (n = 22) and AD (n = 21) cases. Fig. 1e-l) . However, given the identified increase in vessel number in AD, the ratio of PDGFRβ to CD31 load between the AD and control group was also analysed (Fig. 7i ). The PDGFRβ:CD31 load ratio was found to be significantly reduced by 59% (p = 0.005) in AD cases relative to controls, which suggests there is less PDGFRβ per CD31-positive vessel in AD, perhaps reflective of decreased pericyte coverage of neovascular structures in AD.
Discussion
This study is the first to document microglial and neurovascular perturbation without the overt loss of Purkinje cells in the AD neocerebellum. This study utilized high-content analysis methods of neuropathology, glia and neurovascular features on human neocerebellar tissue microarrays (TMAs) from 24 AD and 24 matched control cases. These data were validated by repeating the analysis in thicker freefloating whole sections (3 per case) from 6 AD and 6 control cases. Our results also support the notion that microglial phenotypic change, rather than proliferation, underlies microglial responses in the AD neocerebellum. Furthermore, we provide preliminary evidence of basement membrane-associated extracellular matrix molecular involvement in neocerebellar AD pathogenesis. Finally, we provide evidence to suggest that more CD31/PECAM-1-positive blood vessels are present within the AD neocerebellum, which may impact the ratio of perivascular PDGFRβ to CD31, and ultimately the patency of the vessels. These findings provide evidence that AD-related molecular changes occur within nonneuronal cells of the neocerebellum, which may contribute to the symptomatology and pathophysiology of AD.
Tissue microarray documentation recapitulates neocerebellar neuropathology in AD
Our study of neocerebellar neuropathology using TMAs revealed a considerable increase in amyloid-β expression and load within AD cases, which is in general agreement with earlier studies of AD neuropathology (Braak et al., 1989; Joachim et al., 1989; Dickson et al., 1990; Li et al., 1994; Fukutani et al., 1997; Wegiel et al., 1999; Wang et al., 2002) . Furthermore, no tau-positive neurofibrillary tangles were Fig. 3 . Increase in IBA1 expression and altered IBA1-positive microglial morphology in AD neocerebellum tissue. (a-b) IBA1 levels were found to be significantly elevated in AD (n = 20) compared to control (n = 23) cases in TMA 15, evidenced by (a) a 91% increase in IBA1 integrated intensity (p = .002) and (b) 69% increase in IBA1 load (p = 0.01). (c-f) Whole section analysis was conducted for IBA1 immunoreactivity in 3 neocerebellar sections from control (n = 6) and AD (n = 6) cases. (c) IBA1-positive soma quantification revealed no differences between control and AD cases (p = 0.39). (d) Integrated intensity per IBA1-immunopositive cell significantly increased by 27% (p = 0.03), suggesting elevated protein expression per cell within the AD cerebellum. (e) Measurements of IBA1-positive microglia process length revealed a 22% reduction in length per cell in AD (p = 0.03) compared to controls. (f) Quantification of IBA1 microglial branches demonstrates a 41% reduction in branching number per cell in AD (p = 0.03) compared to controls. (g-h) Representative photomicrographs of IBA1 immunoreactivity in free-floating neocerebellar sections from (g) control case H119 and (h) AD case AZ64 demonstrate elevated IBA1 staining intensity and altered morphologies of IBA1positive microglia in AD. Closer examination of IBA1-positive microglia (soma denoted with white arrows in insets of g-h) illustrates differences in morphology in AD, such as cells being less ramified, possessing fewer branches with retracting processes and widely appearing hypertrophic compared to the ramified microglia in control tissue. Significance values for a-b are based on pvalues from a two-tailed unpaired t-test with Welch's correction for unequal variance. Significance values for c-f are based on a non-parametric two-tailed unpaired Mann-Whitney test. *p < 0.05, **p < 0.01. Scale bar corresponds to 100 μm in g-h and 20 μm for insets. Ctrl = control; AD = Alzheimer's disease; Gra = granule cell layer; Mol = molecular cell layer; IBA1 = anti-ionized calcium-binding adaptor molecule 1.
identified in AD neocerebellar TMA cores, which is in line with previous observations (Joachim et al., 1989; Li et al., 1994; Wegiel et al., 1999; Yamamoto and Hirano, 1985) . However, a small subset of AD cases contained tau-positive circular structures, which could be investigated in future studies to determine the cellular localisation and nature of these structures. Ubiquitin immunoreactivity was identified in both control and AD cores, however, unlike the AD cerebral cortex, ubiquitin was not elevated in the human AD neocerebellum, which widely agrees with previous observations in human tissue (Wang et al., 1991) . A possible explanation for a lack of ubiquitin elevation in the neocerebellum in AD is the absence of neurofibrillary tangles which tend to be decorated with ubiquitin, combined with a lack of proteosomal activity impairment as previously reported in the cerebellum in AD (Keller et al., 2000; Ihara et al., 2012) . In terms of Purkinje cell numbers in AD, the preservation of cells in our neocerebellar TMA is consistent with recent investigations of Purkinje cells, including a design-based stereological study conducted in 10 AD compared with 10 control cerebella (Andersen et al., 2012; Stępień et al., 2012) . Taken together, our data detailing a significant increase in neocerebellar amyloid-β, with no significant changes in tau, ubiquitin, and Purkinje cell numbers analysed in human TMAs recapitulate cerebellar neuropathology previously reported in several studies investigating whole neocerebellar sections. These data justify the rationale of using the TMA approach to investigate other components implicated in the pathogenesis of AD in a tissue-conserving manner, such as the contribution of glial cells and neurovasculature.
Perturbed microglia within AD neocerebellum consists of phenotypic change, not proliferation
Ionized calcium-binding adaptor molecule 1 (IBA1) is a microglial cytoplasmic protein (Imai et al., 1996) . Although IBA1 expression is believed to increase with microglial activation (Ito et al., 1998) where it may be involved in membrane ruffling, phagocytosis and cell mobility (Ohsawa et al., 2000; Ito et al., 2001; Ito et al., 1998; Sasaki et al., 2001) , it is widely considered a pan-marker for microglia, rather than an activated subpopulation (Walker and Lue, 2015) . A recent systematic review summarised the results of twenty papers quantitatively comparing IBA1 between control and AD post-mortem human brains, and it is quite evident that our study is the first to quantitatively compare IBA1 between control and AD neocerebellum (Hopperton Fig. 4 . Presence of deramified dystrophic HLA-DR-positive microglia in AD neocerebellum tissue. (a-b) Integrated intensity and load measurements were used to quantify microglial HLA-DR immunoreactivity in control (n = 24) and AD (n = 23) cases within TMA15. No changes in HLA-DR expression were observed in terms of (a) integrated intensity (ns; p = 0.39) and (b) load (ns; p = 0.11). (c-e) Whole section analysis was conducted for HLA-DR immunoreactivity in 3 neocerebellar sections from control (n = 6) and AD (n = 6) cases. (c) HLA-DR-positive soma quantification revealed no differences between control and AD cases (p = 0.13). (d) Measurements of HLA-DR microglia process length revealed a 33% reduction in length per cell in AD (p = 0.009) compared to controls. (e) Quantification of HLA-DR-positive microglial branches demonstrates a 49% reduction in branching number per cell in AD (p = 0.004) compared to controls. (f-g) Representative photomicrographs of HLA-DR immunoreactivity in free-floating neocerebellar sections from (f) control case H119 and (g) AD case AZ64 demonstrate the abnormal morphology of HLA-DR-positive microglia in AD. Closer examination of HLA-DR positive microglia in AD compared to controls (soma denoted with white arrows in insets of f-g) illustrates shortened, fragmented, deramified and beaded processes, reflecting the appearance of dystrophic HLA-DR microglia in AD. Significance values for a-b are based on p-values from a two-tailed unpaired ttest with Welch's correction for unequal variance. Significance values for c-f are based on a non-parametric two-tailed unpaired Mann-Whitney test. *p < 0.05, **p < 0.01. Scale bar corresponds to 100 μm in f-g and 20 μm for insets. Ctrl = control; AD = Alzheimer's disease; Gra = granule cell layer; Mol = molecular cell layer; HLA = HLA, human leukocyte antigen. et al., 2017). We quantified IBA1 immunoreactivity and reported a significant increase in IBA1 expression and coverage within AD neocerebellar TMA cores. Investigation of IBA1 in whole neocerebellar sections demonstrated no differences in the number of IBA1-positive cells between control and AD cases. However, normalisation of IBA1 integrated intensity to cell number still demonstrated a significant increase in IBA1 expression per cell in AD cases. These data suggest that the increase in IBA1 expression is an indicator of a potential microglial reactive response (Ito et al., 1998; Ito et al., 2001) , occurring in the AD neocerebellum without any overt change in the absolute number of microglia (Hopperton et al., 2017) . We investigated IBA1 cellular morphology and reported a significant reduction in IBA1-positive microglial process length and number of branches within the AD neocerebellum, which further supports the hypothesis that phenotypic change within existing IBA1 microglia, rather than proliferation, contributes towards the glial responses within the human brain (Serrano-Pozo et al., 2013) .
Human leukocyte antigen D-related (HLA-DR) is a type of major histocompatibility complex II (MHCII) expressed on the surface of antigen-presenting cells and is widely responsible for antigen presentation and adaptive immune system activation. HLA-DR is generally Fig. 5 . Quantification of GFAP immunoreactivity in control and AD cerebellar tissue microarray cases demonstrate an absence of astrocytosis in AD. (a-b) Integrated intensity and load measurements were used to quantify GFAP immunoreactivity in control (n = 24) and AD (n = 24) cases within TMA15. No significant differences were observed in GFAP immunoreactivity between control and AD cases in terms of (a) integrated intensity (p = 0.36) and (b) load (p = 0.34). GFAP immunoreactivity was identified in photomicrographs of control and AD TMA paraffin cores, with cell bodies denoted with white arrows in (c) representative control case H148 and (d) AD case AZ57. Closer examination of GFAP-positive astrocytes in AD compared to control cases (soma denoted with white arrows in insets of c-d) illustrates no visible soma hypertrophy or thickening of processes within the AD neocerebellar granule cell layer, suggesting an absence of astrocytosis. Significance values for a-b are based on p-values from a two-tailed unpaired t-test with Welch's correction for unequal variance. Scale bar corresponds to 100 μm in c-d and 20 μm for insets. Ctrl = control; AD = Alzheimer's disease; Gra = granule cell layer; Mol = molecular cell layer; GFAP = Glial fibrillary acidic protein. Integrated intensity and load measurements were used to quantify fibronectin immunoreactivity in control (n = 21) and AD (n = 22) cases within TMA15. (a) A significant 27% increase in fibronectin integrated intensity (p = 0.04) was found in AD TMA cores compared to control cores. (b) No changes in fibronectin load (ns; p = 0.38) were found. (c-d) Representative photomicrographs of fibronectin immunoreactivity in free-floating neocerebellar sections from (c) control case H119 and (d) AD case AZ64 illustrate the higher intensity of immunoreactivity within the molecular layer in AD. (e-f) Higher power insets of panels (c) and (d) illustrate patches of fibronectin immunoreactivity within capillaries, with more intense fibronectin immunolabelling present within AD tissue. White arrows illustrate an absence of fibronectin immunoreactivity, black arrows illustrate the presence of fibronectin immunoreactivity. Significance values for a-b are based on p-values from a two-tailed unpaired t-test with Welch's correction for unequal variance. *p < 0.05, **p < 0.01. Scale bar corresponds to 100 μm in c-d, 50 μm for e-f. Ctrl = control; AD = Alzheimer's disease; Gra = granule cell layer; Mol = molecular cell layer; Fibro = fibronectin. considered a marker of activated microglial cells, though it may have weaker expression in resting microglia (McGeer et al., 1987; Lee et al., 2002) . To date, of the five studies that have quantified HLA-DR immunoreactivity in the cerebellum (either protein expression or cell counts), four studies have found no differences between AD and control cases (Giulian et al., 1995; Lue et al., 2001; Van Everbroeck et al., 2004; Overmyer et al., 1999) . The only study to report a difference was a semi-quantitative pilot study of HLA-DR immunoreactivity in n = 3 control versus n = 3 AD cases (Hensley et al., 1995) . Therefore, our neocerebellar TMA data demonstrating no statistical difference in HLA-DR expression and coverage between control and AD samples is in general agreement with the majority of current studies examining HLA-DR immunoreactivity in the cerebellum. Furthermore, we conducted HLA-DR microglia cell counts in whole neocerebellar sections and found no changes in cell number between control and AD cases. Interestingly, we identified a significant reduction in both HLA-DR cellular process length and number of branches within AD cases, which reinforces the morphological and phenotypic changes underlying the HLA-DR glial response to AD within the neocerebellum. The lack of HLA-DR upregulation or changes in cell number in the AD neocerebellum, combined with the presence of considerable dendritic morphology changes is consistent with the viewpoint that microglial changes in AD are widely due to a phenotypic change of resting microglial cells, rather than the prospect of any proliferation (Serrano-Pozo et al., 2013) .
Absence of astrocytosis in the AD neocerebellum
Glial fibrillary acidic protein (GFAP) is a class III intermediate filament protein generally used as a marker of reactive astrocytosis in pathological conditions (Garwood et al., 2017; Sofroniew and Vinters, 2010) . We investigated if reactive astrocytosis was present in the neocerebellum in AD through quantification of GFAP immunoreactivity. Our results demonstrated no differences in GFAP expression or coverage between control and AD cases, which suggests an absence of reactive astrocytosis in the AD neocerebellum. Our results corroborate an immunohistochemical study of 12 AD and 12 control human brains, which assessed another astrocytic protein also considered a marker of astrocytic activation, S100 calcium-binding protein β (S100β), reporting no changes in the AD cerebellum despite extensive upregulation in cortical regions in AD (Van Eldik and Griffin, 1994) . Furthermore, our results also corroborate a densitometric study of GFAP-positive astrocytes in 10 sporadic AD cases and 10 controls, which reported no differences in the density of GFAP-positive astrocytes in the cerebellar granule layer of the AD cases compared to the control cohort (Fukutani et al., 1996) . The absence of astrocytosis within the AD neocerebellum may be attributable to a lack of cerebellar neurofibrillary tangles (NFTs) present within the tissue. Studies assessing gliosis within the AD cerebral cortex suggest that an increase in the number of astrocytes parallels an increase in the number of NFTs, while the number of GFAP astrocytes have been shown to correlate with the Braak stage of NFTs (Serrano-Pozo et al., 2011; Simpson et al., 2010) . Thus, the lack of GFAP upregulation and NFTs in the AD neocerebellum reinforces the potential pathological relationship between astrocytosis and tau pathology, which can be inferred from human neocortical AD studies (Simpson et al., 2010; Serrano-Pozo et al., 2011; Serrano-Pozo et al., 2013) . Fig. 7 . Increase in CD31-positive vessels in AD neocerebellum tissue. CD31 levels were found to be significantly elevated in AD (n = 20) compared to control (n = 21) cases in TMA 15, evidenced by (a) a 114% increase in CD31 integrated intensity (p = 0.006) and (b) 115% increase in CD31 load (p = 0.001). (c) Quantification of CD31-positive vessel number revealed a significant 98% increase in the number of vessels (p = 0.02) in AD cases compared to controls. (d) Integrated intensity per CD31-positive vessel was unchanged between the control and AD groups (ns; p = 0.69), suggesting no overall differences in CD31-positive protein expression levels in AD. (e-f) Representative photomicrographs of CD31 immunoreactivity in free-floating neocerebellar sections from (e) control case H119 and (f) AD case AZ64 illustrate an increase in the number of CD31-positive vessels in AD. (g-h) Higher power insets of panels (e) and (f) illustrate a greater number of CD31-positive vessels in the AD neocerebellum. White arrows illustrate CD31-positive vessels. (i) The ratio of PDGFRβ:CD31 load was found to be significantly reduced by 59% (p = 0.005) in AD (n = 20) compared to control (n = 20) cases. Significance values for a-d are based on p-values from a two-tailed unpaired t-test with Welch's correction for unequal variance. *p < 0.05, **p < 0.01. Scale bar corresponds to 100 μm in e-f, and 50 μm for g-h. Ctrl = control; AD = Alzheimer's disease; Gra = granule cell layer; Mol = molecular cell layer; CD31 = cluster of differentiation 31.
Increased expression of basement membrane-associated ECM molecules in AD neocerebellum
Currently, there are no studies available which have quantified various components of basement membrane-associated extracellular matrix (ECM) molecules such as collagen IV, or fibronectin within AD neocerebellar samples compared to control brains. Therefore we decided to investigate these molecules within the AD neocerebellum.
Although collagen IV and fibronectin are both proteins secreted by endothelial cells, astrocytes and pericytes found in the periphery and vasculature of the brain, greater fibronectin deposition in the AD neocerebellum with no overt change in collagen IV may be related to differences in the roles of both proteins in the brain. Collagen IV is a structural protein involved in stabilizing and providing strength to the basement-membrane through interacting with other proteins including laminin, nidogen and perlecan (Brachvogel and Mayer, 2004) . Our data suggests that collagen IV is not excessively deposited within the AD neocerebellum, compared to the neocortex, where studies have documented increases in cortical vascular collagen IV (Kalaria and Pax, 1995; Farkas et al., 2000; Lepelletier et al., 2017) .
In contrast to collagen IV, our study demonstrated a significant increase in vascular fibronectin expression within the neocerebellar vasculature using the TMA approach and whole section validation. These results corroborate recent reports of increased fibronectin immunoreactivity within the neocortex (Lepelletier et al., 2017) and previous reports of increased fibronectin within plasma of AD patients (Lemańska-Perek et al., 2009; Muenchhoff et al., 2014) . Fibronectin is a specialized protein involved in several cellular processes including adhesion, migration, proliferation, transformation, matrix remodeling, tissue repair, wound healing and hemostasis (Mao and Schwarzbauer, 2005; Geiger et al., 2001) . Fibronectin also demonstrates a strong angiogenic influence and promotion of survival and proliferation of brain endothelial cells (Wang and Milner, 2006; Milner, 2007) . Therefore, the increase in fibronectin and its established role in endothelial cell survival, proliferation and adhesion is in agreement with our reported increase in blood-vessels immunopositive for human platelet endothelial cell adhesion molecule (CD31), which we discuss in the context of potential angiogenesis/hypervascularisation below.
Neurovascular changes in the AD neocerebellum
Our study is the first to report a quantitative increase in the number of CD31/PECAM-1-positive blood vessels within the AD neocerebellum through TMA analysis. Human platelet endothelial cell adhesion molecule (CD31/PECAM-1) is a transmembrane protein known to be highly expressed by endothelial cells (localised to intercellular junctions), in addition to leukocytes and platelets which in turn are known to be involved in the deposition of amyloid-β and inflammation (Casoli et al., 2010; Gianfranco and Elisabetta, 2004) . Previous studies have shown elevated CD31 levels within the plasma of AD patients compared to controls (Casoli et al., 2010; Nielsen et al., 2007; Xue et al., 2012) . Therefore, we investigated CD31 expression, coverage and number of immunopositive blood vessels within the neocerebellum. Although we initially found an increase in the expression and coverage of CD31 in the AD neocerebellum, these findings were not significant when vessel number was taken into account within the control and AD cohorts, thereby suggesting these changes in expression/coverage are widely attributable to an increase in the number of CD31-positive blood vessels. These results could be an indication of possible angiogenic processes occurring within the neocerebellum as reported in other areas of the human AD brain, including possible hypervascularisation and increased expression of angiogenic factors which warrants further investigation (Buee et al., 1992; Biron et al., 2011; Tarkowski et al., 2002) . Furthermore, whether this increase in the number of CD31-positive blood vessels in the AD neocerebellum is due to an increase in the absolute number of endothelial cells, or other factors which may impact vascular density (such as tissue volume), requires future investigation with high-resolution and design-based stereological techniques.
We also investigated mural cell markers platelet-derived growth factor receptor beta (PDGFRβ) and alpha smooth muscle actin (αSMA) in the AD neocerebellum. We quantified the expression and coverage of PDGFRβ, a marker for capillary-associated pericytes, and α-SMA, a marker for vascular smooth muscle cells around large vessels using the TMA approach. Our data demonstrates that the expression and coverage of PDGFRβ and α-SMA lining the neurovasculature are not altered in the neocerebellum in AD, suggesting wider preservation of neocerebellar vascular mural cells in AD. However, we show for the first time, a reduction in PDGFRβ:CD31 load within the AD neocerebellum, which may suggest that hypervascularisation could be accompanied by failure to invest perivascular cells (Bell et al., 2010) . There is an emerging body of evidence in both AD animal models and patient neuroimaging studies which suggest that neovascular changes in AD occur before cognitive decline, amyloid-β deposition and neuropathology (Iadecola et al., 1999; Knopman and Roberts, 2010; Ruitenberg et al., 2005; Zlokovic, 2011) . Thus, our data supports the notion that neovascular disruption, notably changes affecting basement membrane-associated ECM molecules and endothelial cells, may be a dissociated event from AD neuropathology, as suggested by the scant AD pathology within the neocerebellum in the presence of significant neovascular changes.
Methodological considerations
As with any neuropathological study utilising post-mortem human tissue, there is variability from case to case, or region to region, despite analogous post-mortem processing procedures, which reflects the natural variation associated with studying human subjects (Ferrer et al., 2008) . This variation has been particularly vital in understanding the cellular basis for symptom heterogeneity in other neurodegenerative disorders studied in our laboratory, such as Huntington's disease (Singh-Bains et al., 2019) . One of the variables which cannot be controlled in human neuropathological studies is the primary cause of death for the cases. In the TMA, the most common cause of death for the AD cases were respiratory-related complications including pneumonia (Table 2 ). In comparison, the most common cause of death for neurologically normal control brains were cardiac-related complications (Table 1) . We have published many papers in human Alzheimer's disease and Huntington's disease where these differences are apparent in the case cohorts (Narayan et al., 2015b; Coppieters et al., 2014; Singh-Bains et al., 2019; Mehrabi et al., 2016) . Many studies have reported pneumonia as the most common physiological cause of death for AD patients, and is widely attributable to dysphagia causing the ingestion of food into the respiratory system, leading to aspiration pneumonia (Todd et al., 2013; Kukull et al., 1994; Bosch et al., 2012) . Pneumonia causes significantly more deaths in AD patients than the general population and is a frequent complication in patients with advanced dementia (Todd et al., 2013) . In comparison, ischemic heart disease is the leading cause of death for the general population, including patients without a neurological disease (Bloomfield, 2017) . Therefore, while it is to be acknowledged that the differences in cause of death between the control and AD cohorts may be considered a confounding variable in this study, it can also be argued that pneumonia is in fact a clinical consequence of end-stage AD pathology.
While we matched demographic variables including post-mortem delay and age at death between the control and AD cohorts, we were unable to sex-match cases in this study. Therefore, we conducted additional analyses to investigate the impact of sex differences on the altered microglia and neurovasculature in the AD neocerebellum (Additional file 2: Supplementary Fig. 2a-f ). We compared our IBA1, fibronectin and CD31 expression data between males in females from the pooled TMA data, and separately between the control and AD cohorts. We can conclude that gender has no impact on our reported microglial and vascular changes in the neocerebellum in AD.
Additionally, a future direction would be to understand the possible underlying genetic basis for the altered microglia and neurovasculature in the AD neocerebellum, because of the relevance of the Apolipoprotein E (APOE) genotype for the severity of AD pathology (Iacono et al., 2009; Serrano-Pozo et al., 2013) . A previous study which quantified the absolute numbers of IBA1 positive microglia in a section of human temporal cortex demonstrated that the number of IBA1 positive microglia did not differ between APOE ε4 carriers and non-carriers (Serrano-Pozo et al., 2013) . However, APOE ε4 carriers had a greater number of IBA1-HLADR positive colabeled cells, which could serve as an exciting avenue to pursue in the future using immunohistochemical co-labelling techniques in the neocerebellum. Unfortunately, the Human Brain Bank clinicodemographic information does not include the APOE genetic status of the cases used for the TMA studies. Furthermore, the formalin-fixed paraffin embedded blocks used for the construction of the TMA is optimally processed for immunohistochemistry, and not DNA extraction for genetic studies due to formalin concentration and storage times (Srinivasan et al., 2002) . Therefore, using tissue preservation methods optimized for genomic studies, investigating the impact of the APOE status on microglia and neurovasculature could be an exciting avenue for the future.
Conclusions
In conclusion, this is the first study of its kind to undertake a tissue microarray screening approach as a means to investigate the human neocerebellum in AD. We demonstrate that this approach recapitulates subtle features of neocerebellar AD pathology, including the upregulation of neocerebellar amyloid-β, with no significant changes in tau, ubiquitin, or Purkinje cell number. The lack of neuronal degeneration provided a context to extend our investigation to non-neuronal cells, in order to identify more subtle AD-related molecular changes which would be difficult to detect in more severely degenerated regions. Our investigation of IBA1-and HLA-DR-positive microglia revealed morphological and protein expression changes, with no changes in cellular numbers, reinforcing that microglia do not proliferate in AD, but assume an altered phenotype. We also reported significant basement membrane-associated extracellular matrix molecular changes and neurovascular changes, as evidenced by increased expression of fibronectin with a greater number of CD31-positive vessels in a region of the AD brain traditionally considered to be devoid of major neuropathology. Taken together, these data support the notion that microglial and vascular changes are vital components of disease progression within the neocerebellum. The significant neurovascular and microglial changes occurring without major features of traditional AD neuropathology suggest that these changes occur early in cerebellar AD pathogenesis, independent of neuronal loss and tau-tangle formation. Future studies are needed to determine if these changes are causative, contributing, or a consequence of the disease, which warrants further investigation. Therefore, we conclude the neocerebellum is not a silent bystander in AD, based on our evidence that AD-related molecular changes occur within non-neuronal cells, supporting the hypothesis that there is a cerebellar role in the pathogenesis of AD.
Supplementary data to this article can be found online at https:// doi.org/10.1016/j.nbd.2019.104589.
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